Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.50+0.12 (+3.55%)
Close on Nov 18, 2026Market cap $515.20MP/E –Yield –
Aclaris Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aclaris Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$86.31M. For fiscal 2025 it was -$76.38M. The highest annual figure on record is -$5.26M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$76.38M | – |
| FY2024 | Dec 31, 2024 | -$141.93M | – |
| FY2023 | Dec 31, 2023 | -$97.36M | – |
| FY2022 | Dec 31, 2022 | -$89.85M | – |
| FY2021 | Dec 31, 2021 | -$89.72M | – |
| FY2020 | Dec 31, 2020 | -$50.91M | – |
| FY2019 | Dec 31, 2019 | -$111.06M | – |
| FY2018 | Dec 31, 2018 | -$84.78M | – |
| FY2017 | Dec 31, 2017 | -$54.36M | – |
| FY2016 | Dec 31, 2016 | -$48.57M | – |
| FY2015 | Dec 31, 2015 | -$20.67M | – |
| FY2014 | Dec 31, 2014 | -$8.53M | – |
| FY2013 | Dec 31, 2013 | -$5.26M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.24M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$18.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$99.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.93M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.30M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.53M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.47M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.38M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.55M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$43.60M | – |
| Q1 FY2019 | Mar 31, 2019 | -$27.05M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.04M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.34M | – |
| Q2 FY2018 | Jun 30, 2018 | -$31.98M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.95M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$18.76M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.93M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.63M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.81M | – |
See a number that looks wrong?